Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer

Abstract

<i>HER2</i> amplification in <i>RAS/RAF</i> wild-type mCRC seems to be a predictive biomarker for lack of efficacy of anti-EGFRab therapy. Screening patients with <i>RAS/BRAF</i> wild-type mCRC for <i>HER2</i> amplification should be considered before anti-EGFRab treatment to guide therapy and to identify patients for early referral to clinical trials.